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Abstract
Background: Fibrolytic and profibrotic activities of the matrix metalloproteinases (MMPs)-2 and -9 play a central
role in liver fibrosis. Since binding to the extracellular matrix influences the activity of both gelatinases, here the
role of fibrillar collagens as the most abundant matrix components in fibrotic tissue was investigated.
Results: In situ zymography and immunohistology showed association of enzymatically inactive prodomain-
containing proMMP-2 and proMMP-9 but not of their activated forms to fibrillar collagen structures, which are not
substrates of these gelatinases. In solid-phase binding studies with human collagens and collagen fragments, up to
45% of [
125I]-labeled proMMP-2 and proMMP-9 but not of active (act)MMP-2 and actMMP-9 were retained by
natural collagenous molecules and by synthetic analogs containing repeated Gly-Pro-Hyp triplets (GPO). Surface
plasmon resonance yielded binding constants for the interaction of collagen type I (CI) with proMMP-2 and
proMMP-9 in a nanomolar range. Values for actMMP-2 and actMMP-9 were 30-40 times higher. Tenfold molar
excesses of (GPO)10 reduced the interaction of CI with pro- and actMMP-2 by 22- or 380-fold and resulted in
prodomain release accompanied by high enzymatic activation and activity. Pointing to gelatine substrate
displacement, higher (GPO)10 concentrations blocked the enzymatic activity. The MMP-2 prodomain-derived
collagen-binding domain peptide (P33-42) binds to the collagen-binding domain of MMP-2, thereby preserving
enzymatic inactivity. Synthetic P33-42 peptide competed with proMMP-2 binding to CI and prevented (GPO)10-
mediated proMMP-2 activation. In contrast to (GPO)10,P 33-42 did not activate proMMP-2, making triple helical and
hydroxyproline-containing (GPO)10 unique in modulating gelatinase availability and activity.
Conclusions: These findings suggest novel strategies using collagen analogs for the resolution of liver fibrosis via
fibrotic matrix-sequestered gelatinases.
Background
Matrix metalloproteinases (MMPs) form a large family
of zinc-dependent metalloendopeptidases that degrade
extracellular matrix (ECM) molecules, including various
collagens, gelatine, elastin, fibronectin and aggrecan [1].
The diversity of MMP-binding partners and of MMP
substrates suggests a central role for MMPs in the
“protease web” beyond their proteolytic activity. MMPs
were described to be involved in the regulation of cellu-
lar differentiation, proliferation and migration, the regu-
lation of growth and metastasis of tumors, and the
regulation of organ fibrosis (for example, liver) [2-4]. All
MMPs consist of three domains, including the catalytic
domain with a zinc-binding active-site motif, the prodo-
main with a conserved cysteine interacting with the
catalytic zinc to maintain the latency of the enzymati-
cally inactive latent proform of MMPs (proMMPs), and
the hemopexin-like domain functional in substrate bind-
ing and in the interaction with tissue inhibitors of
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domain, the gelatinases MMP-2 and MMP-9 contain
the additional fibronectin type II modules Col-1, Col-2
and Col-3 [5], forming collagen-binding domains
(CBDs) that specifically interact with collagens, with
other ECM molecules and with the prodomain. As for
differences in gelatinases, only MMP-2 but not MMP-9
has collagenolytic activity, and a distinct MMP-2 prodo-
main peptide (P33-42) conserves latency upon interaction
with the CBD [6,7]. Here a combination of the sequence
and the thermal stability of their substrate, exemplified
by denatured nonhelical gelatine defines specificity [8].
MMP-2 localized at the cell surface interacts with col-
lagen type IV (CIV), CD44, integrin receptors and the
discoidin domain receptor 2 [4,9,10]. MMP-2 binds to
native or denatured collagens, elastin, fatty acids and
thrombospondins via its CBD exosite [11,12].
MMPs are assumed to be sequestered in the ECM
[13,14]. Recently, we established the a2 chain of col-
lagen type VI as the main binding structure for seques-
tration of collagenases and stromelysin-1 proforms in
fibrotic tissue [15]. Gelatinase binding sites were
assumed to be within the rigid triple-helical collagen
structure and thus far have been described only at the
oligopeptide level [7,16]. As for the a1 chain of collagen
type I (a1(I)), the hydroxyproline (Hyp)-containing pep-
tide segment P713 was identified as an exosite CBD
ligand of MMP-2 [17].
The current view of progressive liver fibrosis includes
neutralization of potentially matrix-degrading MMPs by
an even higher expression of TIMPs. On the other
hand, in the fibrosis resolution phase, MMP-2 activity in
serum [18] and liver tissue [19] is high and high serum
levels of MMP-9 and MMP-2 were found as early as 6 h
after hepatectomy [20]. These observations pointed to a
pool of ECM-stored MMPs as recently shown for col-
lagenases [15].
The aim of this study was to characterize non-substrate-
binding structures for gelatinase in the ECM and the
potential of synthetic collagen-like binding competitors to
modulate MMP availability or activity through exosite
interaction in fibrotic diseases. Our data suggest that col-
lagen analog-driven conformational changes of the MMP
molecule are triggered by high-affinity interaction of col-
lagen analogs with the CBD, eventually leading to MMP
activation that ultimately abrogates proMMP binding to
nonsubstrate collagens. We found the collagen-immanent
secondary triple-helical structure and the modified amino
acid Hyp to be prerequisite for gelatinase binding.
Results
Collagen fibers in cirrhotic liver tissue retain gelatinases
Thioacetamide-intoxicated rats developed liver cirrhosis
with extensive deposition of scar tissue in expanding
fibrotic septa showing typical extensive bridged fibrosis,
in which collagen types I and III (CI and CIII) predomi-
nate (Figures 1A and 1B). In in situ zymography with
dye quenched (DQ)-gelatine, strong gelatinolytic activity
was associated with these structures, as shown by the
bright fluorescence aligned with fibrillar structures
(Figures 1C and 1D). In the liver, MMP-2 is mainly
expressed by hepatic stellate cells, whereas Kupffer cells
are the major cellular source for MMP-9. Human
fibrotic tissue was stained with monoclonal antibodies
specific for MMP-2 or MMP-9 and subjected to a strin-
gent washing procedure (Figures 1E-H). Light MMP-2
labeling was detected in fibrotic septa, and more pro-
nounced MMP-9-specific labeling was observed in the
pericellular region of macrophage-like cells (Figure
1E-G). The ubiquitous fibrillar staining observed for
MMP-2 and the pericellular deposition of MMP-9 sug-
gested fibrillar collagens or associated ECM molecules
to have the capacity to store MMPs. No significant
binding was observed when sections were preincubated
with the aminophenyl mercuric acetate (APMA)-
activated form of MMP (actMMP)-2 or actMMP-9 (not
shown). If sequential liver sections were preincubated
with prodomain-containing proMMP-2 or proMMP-9,
preferential staining of fibrotic septa was observed for
both gelatinase proforms (Figures 1F-H), confirming the
localization of gelatinolytic activity observed by in situ
zymography.
ProMMP-2 and ProMMP-9, but not actMMP-2 and
actMMP-9, strongly bind to immobilized native collagens,
CI fragments and to Hyp-containing collagen analogs
To further elucidate the interaction of human ECM com-
ponents with human pro- or actMMP-2 or pro- or
actMMP-9, we studied the retention of recombinant
[
125I]-labeled and enzymatically active gelatinases (Figure
2A) by highly purified and well-characterized native fibril-
lar collagens, CI fragments and Hyp-containing collagen
analogs. Serial dilutions of potential non-substrate-binding
partners dotted to a nitrocellulose membrane with high
protein-binding capacity showed that natural and synthetic
collagen structures sufficiently bound proMMP-2 and
proMMP-9 (not shown) (Figure 2B). In this qualitative
analysis, comparable signal intensities were observed for
proMMP-2 binding to 0.25 to 0.5 μg / d o tC Io rC I I Ia n d
from 2 to 4 μg/dot of the tightly packed helical Gly-Pro-
Hyp (GPO)10 (Figure 2B, left). The binding efficiencies of
proMMP-2 to a1(I)-derived CB fragments declined in the
following order: CB7>CB6>CB8> > CB3. Regardless of the
collagenous structure immobilized, only weak binding was
found for actMMP-9 (not shown) and for actMMP-2 (Fig-
ure 2B, right).
In the next step, [
125I]-labeled proMMP-2 and
proMMP-9 were applied to microwell-immobilized
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Page 2 of 15collagen structures, and retained radioactivity was deter-
mined after thorough washing to estimate gelatinase
binding (Table 1). Again, proMMP-2 and proMMP-9
strongly bound to CI as well as to single chains of CI
and CIII (range, 22% to 45%). Confirming the results
from the dot-blot analysis, a maximum binding of only
19% was found for actMMP-2 to the a1(I) chain,
whereas no binding of actMMP-9 to collagenous struc-
tures was observed. The Hyp-containing (GPO)10 pep-
tide, which structurally resembles triple-helical collagen
helices with high melting temperatures, was used to
further elucidate the relevance of the GPO triplet for
proMMP-2 and proMMP-9 binding. Triple-helical
Gly-Pro-Pro (GPP)10, devoid of Hyp, and the linear
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Figure 1 Localization of gelatinolytic activity in fibrotic liver tissue. (A and B) Collagenous septa in fibrotic rat liver tissue were stained with
Sirius red with rectangular detail that highlights collagen fibers in (B). Original magnification, ×20. (C and D) In situ zymography localizes strong
gelatinolytic activity to fibrous structures with rectangular detail that demonstrates nonpericellular, fiber-associated gelatinase activity in (D).
Original magnification, ×40. (E-H) Cryostat sections of fibrotic human liver tissue were incubated with 25 ng of proMMP-2 (F) or proMMP-9 (H)
or were left untreated (E and G). Bound matrix metalloproteinases (MMPs) were detected using immunohistochemistry monoclonal antibodies
specific for MMP-2 (arrows in E and F depict endogenous MMP expression) or MMP-9 (G and H). An irrelevant primary antibody served as a
control (I). Sections shown represent three independent experiments. Scale bars, 100 μm.
Ruehl et al. Fibrogenesis & Tissue Repair 2011, 4:1
http://www.fibrogenesis.com/content/4/1/1
Page 3 of 1572
96
MMP-2
66
43
32
84
MMP-9
gel zymography autoradiography
kDa
[125I]: - - ++ - - ++
pro act pro act
A
dotted:
CI
CIII
CVI
D1(I)
D2(I)
CB3
CB6
CB7
CB8
(GPO)10
(GPP)10
GAP
incubated:
μg/dot
4 2 0.13 0.25 1 0.5 4 2 0.13 0.25 1 0.5
[125I]-proMMP-2 [125I]-actMMP-2
B
Figure 2 Quality control of [
125I]-(un)labeled pro/actMMP-2/-9 and dose-dependency of pro/actMMP-2-binding to nitrocellulose-
immobilized collagenous molecules. (A) Unlabeled or [
125I]-labeled pro/actMMP-2/-9 (~1 ng) were quality-checked in substrate gel
zymography (left) before the dried gel was subjected to autoradiography (right). Note that after [
125I]-labeling, MMP structure and activity
remained unchanged. (B) Serial dilutions of collagens or collagen type I (CI) derivatives dotted to a nitrocellulose membrane were incubated
with 5 ng of [
125I]-labeled pro/actMMP-2 before thorough washing. Bound MMP was monitored by autoradiography. Images shown represent
three independent experiments.
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Page 4 of 15Gly-Ala-Pro (GAP) peptide served as controls. Com-
pared to the respective actMMP, proMMP-2 and
proMMP-9 bound two- to sevenfold more strongly to
(GPO)10, but both forms of the MMPs showed only
marginal interactions with the control peptides (GPP)10
and linear GAP (Table 1).
Repeated GPO peptides interfere with binding of
proMMP-2 and proMMP-9 to CI
The kinetics of gelatinase binding to CI were deter-
mined by surface plasmon resonance (SPR) measure-
ments. The linear control peptide GAP had no effect on
the interaction of the MMPs with CI (not shown). As
for the assumed binding competitor (GPO)10, Kd values
were determined using standard conditions for SPR
measurements (Table 2). These nonactivating conditions
without divalent metal ions are known to interfere with
MMP activity and conformation. Since the Off rates for
proMMP-2 and actMMP-2 binding to CI were in the
same range (0.48 s
-1), the reduced binding strength of
actMMP-2 (Kd, 170 ± 5 nM) compared to proMMP-2
(Kd, 70 ± 3 nM) was due to differences in the On rates.
The effects seen with MMP-9 were more dramatic,
since actMMP-9 bound to CI (Kd,8 7 0±3 9n M )s e v e n -
fold less effectively than proMMP-9 (Kd, 120 ± 9 nM).
A 10-fold molar excess of (GPO)10 only slightly
impaired the binding of proMMP-2 and actMMP-2 to
CI but had more pronounced effects on proMMP-9
(Table 2). Using MMP activity buffer conditions, addi-
tion of (GPO)10 abolished binding of proMMP-9 to CI
(Figure 3A), and (GPO)10 treatment of proMMP-2 led
to a reduction in resonance units below baseline levels
(Figure 3B). Since under these conditions actMMP-2
effectively degraded the CI matrix with a final loss of
about 400 resonance units after 60 s (not shown), the
sensorgram of proMMP-2 in the presence of (GPO)10
(Figure 3B) was most likely due to (GPO)10-induced col-
lagenolytic MMP-2 activity, which is absent with MMP-
9 (Figure 3A).
Binding of MMP-2 to CI strictly depends on the gelatinase
activation status
Since Kd values for binding of proMMP-2 to CI in the
presence of (GPO)10 could not be assessed under acti-
vating buffer conditions, we studied proMMP-2 and
actMMP-2 binding to immobilized CI in MMP activity
buffer containing Ro 28-2653 that specifically inhibits
proMMP (auto)activation and MMP enzymatic activity.
The effects of strong binding of latent gelatinases to CI
reduced by MMP activation were observed to be highly
aggravated using this optimized buffer. ProMMP-2
bound to CI within low nanomolar Kd values represent-
ing a 10-fold binding enhancement, whereas the reduc-
tion of binding upon MMP activation was elevated from
2.5- to 35-fold (Figures 3C and 3D; Tables 2 and 3).
Here the addition of (GPO)10 to proMMP-2 resulted in
a 22-fold reduced affinity for CI (Figure 3C), which was
in the same range observed for MMP-2 activation
(Table 3).
ProMMP-2 activation and actMMP-2 activity are impaired
upon CI binding and are strongly enhanced in the
presence of (GPO)10
To further investigate the activation of MMP-2 by
(GPO)10, the cleavage of a short, gelatinase-specific
Table 1 Binding of pro- or actMMP-2 or pro- or actMMP-
9 to native collagens, single chains of CI, chain
fragments and synthetic peptides
a
Binding of [
125I]-MMPs (% of maximum control)
ActMMP-2 ActMMP-9 ProMMP-2 ProMMP-9
Wells coated with
CI 11.1 ± 1.8 3.1 ± 0.5 24.0 ± 5.6 30.9 ± 3.1
CIII 14.3 ± 5.8 5.0 ± 0.4 40.0 ± 5.0 45.0 ± 2.0
CVI 4.8 ± 0.6 2.4 ± 0.1 14.1 ± 1.8 12.3 ± 0.8
a1(I) 19.0 ± 3.0 4.7 ± 0.3 36.0 ± 4.0 37.6 ± 0.9
a2(I) 10.7 ± 1.8 2.6 ± 0.2 30.2 ± 2.3 21.8 ± 1.1
a1CB3 7.4 ± 0.3 1.8 ± 0.2 13.2 ± 7.9 7.4 ± 1.2
a1CB6 4.9 ± 1.5 2.4 ± 0.2 12.8 ± 2.6 19.3 ± 0.4
a1CB7 6.8 ± 0.6 2.1 ± 0.3 18.2 ± 3.7 20.4 ± 1.3
a1CB8 4.4 ± 1.7 2.8 ± 0.4 14.0 ± 4.5 31.6 ± 0.9
(GPO)10 6.2 ± 3.1 5.4 ± 0.6 13.0 ± 3.5 36.1 ± 1.7
(GPP)10 2.1 ± 0.7 0.9 ± 0.4 3.6 ± 2.0 4.9 ± 0.7
GAP 1.5 ± 0.7 0.7 ± 0.2 1.7 ± 1.0 1.3 ± 0.2
aProteins and peptides were immobilized to the wells of polystyrene
microtiter plates before 2 ng/well [
125I]-MMPs were added. Wells were washed
thoroughly, and bound MMPs were determined as residual radioactivity.
Binding efficiency was calculated in comparison to the amount of the
respective radiolabeled MMPs initially added (100%). Results are mean values
± SD of at least five independent experiments performed in triplicate.
activated form of MMP (actMMP); proMMPs, inactive latent proform of MMPs;
MMP, matrix metalloproteinase; CI, collagen type I; a1(I), a1 chain of collagen
type I (a1(I)); a1CB3, a1CB3, cyanogen bromide peptide 3 of the a1 chain of
collagen type I;; GPO, Gly-Pro-Hyp triplets; GPP, Gly-Pro-Pro; GAP, Gly-Ala-Pro.
Table 2 Effect of soluble (GPO)10 on the binding of pro-
or actMMP-2 or pro- or actMMP-9 to CI
a
Binding to CI
Without (GPO)10 10× (GPO)10
Off rate (s
-1) Kd (μM) Off rate (s
-1) Kd (μM)
MMP-2 Pro 0.48 0.07 ± 0.03 0.37 0.10 ± 0.04
Act 0.48 0.17 ± 0.05 0.56 0.21 ± 0.15
MMP-9 Pro 0.32 0.12 ± 0.09 0.22 1.22 ± 0.64
Act 0.76 0.87 ± 0.39 0.61 1.79 ± 1.81
aMatrix metalloproteinases (MMPs) (100 nM) were passed over collagen type I
(CI) immobilized to a sensor chip in the presence or absence of a 10-fold
molar excess of Gly-Pro-Hyp triplets (GPO)10. MMP self-activation and activity
were prevented by a buffer system consisting of phosphate-buffered saline
and 0.05% (vol/vol) Tween 20. Kd values and off rates of MMP binding to CI
were determined by surface plasmon resonance (SPR) analysis and are shown
as mean values ± SD from at least three experiments.
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Page 5 of 15substrate by proMMP-2 and actMMP-2 was measured
with and without a 10-fold excess of (GPO)10.I na d d i -
tion, some experiments used wells coated with fibrillar
CI to explore its effects on activation and activity of
MMP-2. Conversion of the quenched substrate peptide
over time depended on the activation state of MMP-2.
Activation of proMMP-2 (Figure 4A) showed sigmoid
and activity of actMMP-2 (Figure 4B) immediate
exponential kinetics of substrate turnover, probably
due to an activation lag phase for proMMP-2. There
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Figure 3 Binding of pro/actMMP-2/-9 to CI in the presence or absence of 10-fold molar excesses of Gly-Pro-Hyp triplets (GPO)10 and
MMP inhibitor. (A) ProMMP-9 and (B) proMMP-2 (25-150 nM) with or without a 10-fold molar excess of (GPO)10 in MMP activity buffer were left for
15 min on ice before being subjected to surface plasmon resonance (SPR) analysis with CI immobilized to a sensor chip. Association kinetics were
changed to dissociation kinetics after 30 s. Pro(C)/act(D)MMP-2 (25-150 nM) with or without a 10-fold molar excess of (GPO)10 in MMP activity buffer
containing 1 μM Ro 28-2653 were subjected to SPR analysis as described for (A and B). Association kinetics were changed to dissociation kinetics after
60 s. Plots after background subtraction from one experiment and one MMP concentration are shown from three independent experiments.
Table 3 Effect of thermostability and Hyp content of collagen analogs on the binding kinetics of pro- or actMMP-2 to
CI
a
Kd for binding to CI (in nM) in the presence of 10-fold molar excess
- (GPP)10 (POG)5 (GPO)10
ProMMP-2 7.1 ± 0.1 42.1 ± 39.1 155.5 ± 40.3 155.5 ± 50.2
ActMMP-2 250.0 ± 30.0 n.d. n.d. 2,710.0 ± 90.0
aPro- or actMMP-2 (100 nM) was passed over collagen type I (CI) immobilized to a sensor chip in the presence or absence of 10-fold molar excesses of (GPP)10,
(POG)5, or (GPO)10. Reagents were dissolved in matrix metalloproteinase (MMP) activity buffer, and MMP-2 activity was specifically blocked by 1 μM Ro 28-2653.
Kd values of MMP-2 binding to CI were determined by surface plasmon resonance (SPR) analysis and are shown as mean values ± SD from at least three
experiments. Hyp, hydroxyproline; GPP, Gly-Pro-Pro; GPO, Gly-Pro-Hyp triplets; n.d., not determined.
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and actMMP-2 due to association with CI, showing
that binding to fibrillar collagen results in impaired
(auto)activation and activity of the enzyme (Figure 4
hatched curves). Either on bovine serum albumin
(BSA) or on CI, addition of (GPO)10 to proMMP-2
(Figure 4A, bold lines) resulted in the same plateau
activity as actMMP-2 without (GPO)10 (Figure 4B,
thin line). Since substrate freshly added after 120 min
did not alter the outcome and excluded substrate
depletion (data not shown), an elevated substrate turn-
over in the presence of low molar excesses of (GPO)10
was suggested.
The Hyp content defines the efficiency of a competitor
for proMMP-2 binding to CI
Further studies on the proMMP-2 exosite ligand-bind-
ing structure focused on the role of the triple helix
and the Hyp content of the repeated triplet. Midpoints
of melting curves of (POG)10 and (PPG)10 occurred at
64°C and 43°C, respectively. The control peptides
GAP and (POG)5 were confirmed to be found nonhe-
lical even at 5°C (Figure 5). Triple-helical (GPP)10
without Hyp residues was much less efficient in com-
peting with proMMP-2 binding to CI than the nonhe-
lical (POG)5 (Table 3). The competition potency of
(GPO)10 that was triple-helical and contained Hyp
residues was comparable to that of (POG)5.T h e s e
results emphasize the crucial role of GPO triplets for
gelatinase binding and established a 10-fold molar
excess of (POG)5 in relation to proMMP-2 as a mini-
mum prerequisite for blockade of proMMP-2 binding
to fibrillar CI.
(GPO)10 and the MMP-2 prodomain peptide P33-42
compete for binding to the CBD
Collagen analogs similar to (GPO)10,a sw e l la st h e
proMMP-2 prodomain-derived peptide P33-42,a r e
known to bind with high affinity to the Col-modules of
the CBD of MMP-2. Addressing mechanisms of (GPO)
10-induced inhibition of proMMP-2 binding to fibrillar
collagen and (GPO)10-induced enzymatic activation, we
used (GPO)10 and P33-42 to interfere with proMMP-2
binding to CI and to modulate CBD-dependent DQ-
gelatine degradation of MMP-2.
In SPR measurements P33-42 was evaluated as a com-
petitor of proMMP-2 binding to immobilized CI. High
molar excesses of P33-42 increased the Kd values of
p r o M M P - 2b i n d i n gt oC It ou pt o5 0 %( F i g u r e6 A ) ,
which is moderate in comparison to the 22-fold inhibi-
tion in the presence of (GPO)10 (Table 3). On the
other hand, (GPO)10 and P33-42 had different effects on
0
200
400
600
800
1000
0 2 04 06 08 0 1 0 0 120
time (min)
e
n
z
y
m
a
t
i
c
a
c
t
i
v
i
t
y
(
R
F
U
)
0 20 40 60 80 100 120
(GPO)10 CI
+
+ +
-
--
-
+
A B
Figure 4 Activation and activity of pro/actMMP-2 in the
presence of (GPO)10 and immobilized CI. (A) Activation of
proMMP-2 (50 ng) or (B) activity of fully activated actMMP-2 alone
or mixed with 10-fold molar excesses of (GPO)10 was determined in
CI- or bovine serum albumin (BSA)-coated wells with 800 nM MCA-
Pro-Leu-Gly-Leu-Dnp-Dap-Ala-Arg-NH2 substrate. Conversion of the
fluorogenic substrate was monitored over time (data collection rate
min
-1) at 37°C. Graphs represent mean values of three independent
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Figure 5 Polarimetric determination of melting temperatures
of collagen analogs. Spontaneous triple helix assembly of collagen
analogs was assessed by the midpoints of melting curves in a
temperature regimen from 8°C to 60°C for Gly-Ala-Pro (GAP), (POG)5
and (PPG)10 and from 8°C to 90°C for (POG)10. Graphs shown
represent three independent experiments.
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Substrate zymography showed a faint band of prodomain-
free actMMP-2 in the presence of (GPO)10 which did not
occur if proMMP-2 was treated with P33-42 (Figure 6B). In
MMP activity assays with DQ-gelatine as a fluorogenic
substrate, actMMP-2 used as positive control established
a plateau level of substrate conversion of about 1,000 rela-
tive fluorescence units while baseline levels for proMMP-
2 were at about 200 relative fluorescence units. Whereas
DQ-gelatine cleavage was significantly enhanced by 50- to
100-fold molar excesses of (GPO)10,P 33-42 had no activat-
ing effect but a slight inhibitory effect (Figure 6C). The
150-fold excesses of P33-42 or (GPO)10 in relation to
proMMP-2 resulted in a more enhanced inhibitory effect
of P33-42 and a (GPO)10-driven shift from an active MMP-
2 to an enzymatically blocked enzyme (Figure 6C). To
gain insights into the mechanism of action, equimolar
mixtures of (GPO)10 and P33-42 were added to proMMP-2
before assaying DQ-gelatine degradation (Figure 6D). At
50- to 100-fold molar excesses compared to proMMP-2,
P33-42 drastically diminished the activating effect of (GPO)
10 on proMMP-2. In addition, at a 150-fold molar excess
of the mixture to proMMP-2, the inhibitory effect of
(GPO)10 on MMP-2 activity was diminished (Figure 6D).
These findings indicated that both (GPO)10 and P33-42
compete for the same proMMP-2 exosite.
(GPO)10 prevents proMMP-2 binding and releases
proMMP-2 in situ bound to fibrillar septa
To answer the question about the capacity of (GPO)10 to
modulate proMMP-2 binding to fibrillar structures in
situ, cryostat sections of cirrhotic liver tissue were treated
with exogenous Cy2-labeled proMMP-2 (Figure 7). With-
out (GPO)10, the fluorescence pattern (Figure 7B)
reflected the extent of fibrillar collagenous structures
(Figure 7A), confirming that proMMP-2 can be extracel-
lularly stored in fibrotic liver tissue. Coincubation of
(GPO)10 with Cy2-proMMP-2 (Figure 7C) or subsequent
treatment of ECM-bound Cy2-proMMP-2 with (GPO)10
(Figure 7D) either prevented gelatinase binding or pro-
moted effective release of the sequestered enzyme.
Discussion
The ECM is known as a depot for cytokines, as described
by the term crinopexy [21], and as a reservoir for regulative
matrix fragments, for example, classified by the terms
degradomics and endogenous inhibitors of angiogenesis
[22,23]. Proteolytic processing of bioactive molecules is
mainly performed by MMPs. In pathological processes
such as organ fibrosis, this fine-tuned tissue homeostasis is
lost. Because of chronic wounding, inflammation scar tis-
sue accumulates. Its degradation is hampered by the over-
expression of TIMPs and by the blockade of ECM-
degrading activity via binding of latent MMPs to defined
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Figure 6 Comparison of the effects of MMP-2 prodomain-
derived collagen-binding domain (CBD)-binding peptide (P33-
42) and (GPO)10 on proMMP-2 binding and activation. (A) Up to
100-fold molar excesses of P33-42 were mixed with 100-250 nM
proMMP-2 in MMP activity buffer. Enzymatic activity was specifically
blocked by 1 μM Ro 28-2653 before passing over CI immobilized to
a sensor chip. Kd values were calculated from the sensorgrams for
each P33-42 concentration and are shown as mean values ± SD. (B)
Mixtures of 50 ng of proMMP-2 with P33-42 or (GPO)10 were
subjected to substrate gel zymography after 2-h incubation at room
temperature. ProMMP-2 (72 kDa) or actMMP-2 (62 kDa) after
treatment of proMMP-2 with aminophenyl mercuric acetate served
as controls for the activation state. Shown is one representative of
three independent experiments. (C) Dye quenched (DQ)-gelatine
was incubated with 10 ng of proMMP-2 in MMP activity buffer in
the presence of up to 150-fold molar excesses of (GPO)10 or P33-42.
After 5 h at 25°C, end point fluorescence was determined. Results
are mean values ± SD of three independent experiments. (D)
ProMMP-2 was added to up to 150-fold molar excesses of (GPO)10
alone or to equimolar mixtures of P33-42 and (GPO)10 before
incubation with DQ-gelatine. Substrate cleavage as measured after 5
h at 25°C was calculated in relation to proMMP-2 alone (100%).
Results are mean values ± SD of three independent experiments.
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lagenases [15] and, as reported here, fibrillar collagens for
gelatinases. Thus, the ECM contributes to the availability
and activity of its degrading enzymes by storing the inac-
tive collagenase and gelatinase proforms. To break this
vicious cycle of enhanced scar matrix production and
accompanied blockade of MMP activity, we here propose
short synthetic collagen analogs to release matrix-stored
collagen-degrading enzymatic activity.
In situ gelatinolytic activity of proMMP-2 and proMMP-9
collocalizes with fibrotic fibers
Apart from the well-known cell membrane localization of
gelatinases [9], we demonstrated by in situ zymography
fibril-associated gelatinolytic activity and identified it
immunohistochemically as MMP-2 and MMP-9. Since
neither method could discriminate inactive proforms
from activated gelatinases, sections of human cirrhotic
liver were preincubated with recombinant pro- or
actMMP-2 or pro
- or actMMP-9, demonstrating that
only the inactive gelatinase proforms efficiently bound to
the collagenous septa in situ (Figure 1). These findings
are in line with previous reports describing a “distinct
pool” of collagen-bound proenzyme which “appears
recalcitrant to cellular activation” and a reduction of
autolytic inactivation by binding to CI [13,14].
Collagen binding is strongly diminished upon proMMP-2
and proMMP-9 activation
Earlier structural analysis of proMMP-2 revealed a con-
formational transition from an inactive, “closed”
proMMP-2 to an “open” actMMP-2 [24,25]. This activa-
tion-related conformational switch also implicated a
shift in exosite binding affinities of the gelatinases.
Indeed, high binding affinity of the proforms to nonsub-
strate collagens at least by af a c t o ro f3 5r e d u c e dt h e
affinity of actMMP-2 (Tables 1, 2 and 3 and Figure 2B)
and supported this assumption. In addition, the “closed”
conformation benefited from the high-affinity binding to
nonsubstrate fibrillar CI insofar as (auto)activation of
proMMP-2 and proMMP-9 is delayed (Figure 4). Impor-
tantly, this activation can be alleviated not only by gela-
tine binding as described earlier [26] but also by
competing the proMMP exosite interactions with CI by
defined low-molecular-weight, Hyp-containing, triple-
helical short collagen analogs (Figure 4). Thus, autolysis
of MMP-2 slowed because of binding to CI [14], and
substrate turnover, especially for short substrates, is
enhanced by (GPO)10. Our data also pointed to the
importance and interdependency of conformational
switches and enzymatic activation, which were initially
more or less excluded because of the absence of divalent
cations, resulting in only marginally diminished binding
of proMMP-2 to CI despite the presence of (GPO)10
(Tables 2 and 3).
Interestingly, addition of (GPO)10 to proMMP-2 not
only affected the binding and gelatinolytic activity of
proMMP-2 but also confirmed the collagenolytic poten-
tial of MMP-2 (Figure 3B) [6], whereas the loss of CI
binding affinity of proMMP-9 in the presence of (GPO)
10 was not accompanied by CI degradation (Figure 3A),
which is in contrast to a recent publication [27].
On the matrix site, triple helicity and Hyp are important
for strong proMMP-2 and proMMP-9 exosite interaction
Generally, collagens comprise the repeated triplet
sequence (Gly-Xaa-Xaa’)n.I ns t a b l et r i p l eh e l i c e s ,t h e s e
triplets contain a high proportion of the imino acids Pro
and Hyp at the Xaa/Xaa’ positions [28]. Complementing
previous reports [29], screening with highly purified
liver ECM components proved fibrillar CI and CIII to
be good as well as microfibrillar CVI to be inferior
ligands for proMMP-2 and proMMP-9 (Table 1 and
Figure 2B). Assuming that retention of proMMPs might
depend on the secondary structure of the collagen, par-
ticularly on the collagen triple helix, we investigated cor-
relations between its thermal stability and the affinity of
MMP-2 and MMP-9 binding.
Starting from the soluble human placenta-isolated tri-
ple-helical portion of CI with a melting temperature of
33.8°C [30], we found high binding affinity to proMMP-
2 and proMMP-9 with Kd values in a low nanomolar
range (Tables 2 and 3). We tested a1(I) chains, which
rapidly refold into triple-helical conformation in neutral
buffers at room temperature, as well as CB-peptides of
the a1(I) chain, where the length of the triple helix
affects their thermal stability [31]. Here the strength of
D C B A D C B A
Figure 7 (GPO)10-mediated release of proMMP-2 sequestered
in cirrhotic liver tissue. (A) Cryostat sections of cirrhotic human
liver tissue were fixed, stained with Sirius red for collagens and
counterstained with Haemalaun. (B-D) Serial sections of the same
liver tissue sample were incubated with 60 ng of Cy2-proMMP-2 in
the dark for 24 h before unbound Cy2-proMMP-2 was removed by
washing. (B) Slides were treated with Cy2-proMMP-2 alone. (C) Cy2-
proMMP-2 was mixed with a 10-fold molar excess of (GPO)10 before
being added to the slides. (D) Cy2-proMMP-2 was allowed to bind
before a 10-fold molar excess of (GPO)10 was applied. Original
magnification, ×40; scale bars, 200 μm.
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directly correlated to the thermal stability of its triple
helix that was defined by the overall size and by the
GPP/O content of the peptide (Table 1). Short synthetic
collagen analogs with increasing triple helicity and Hyp
content confirmed the findings for the CB peptides (Fig-
ure 2B and Table 1). Keeping the development of syn-
thetic lead structures to modulate proMMP binding to
collagen in mind, we tested short soluble natural and
synthetic collagen structures as competitors of
proMMP-2 and proMMP-9 binding.
At low molar excesses, not only the CI-derived CB7
(not shown) but also synthetic (GPO)10 (Table 3) were
found to effectively compete proMMP-2 binding to CI.
Addition of just a 10-fold molar excess of (GPO)10 to
CI-bound proMMP-2 resulted in a more than 20-fold
increase in Kd values, while (GPP)10 and GAP were less
efficient. While short nonhelical (POG)5 (Figure 5)
increased the Kd value of binding 22-fold, triple-helical
(GPP)10 induced about a sixfold increase (Table 3).
Thus, the combined presence of Hyp residues and a
stable triple-helical structure might explain the efficacy
of (GPO)10 as a competitor of the gelatinase-CI binding.
Subsequent experiments emphasized the Hyp content of
the triple helix as the major prerequisite for strong
interference with the binding of proMMP-2 and
proMMP-9 to CI (Table 3).
We hypothesize that proMMP binding to GPO triplets
in collagens resembles the binding of platelet glycoprotein
VI or leukocyte-associated immunoglobulin-like receptor
1 to collagens, showing stronger binding of platelet glyco-
protein VI to (GPO)4-10 as compared to (GPP)10 [32,33].
Binding constants of proMMP-CI interaction in the
nanomolar range suggest binding cooperativity of CBD
modules
Functionally, the CBD is critical for positioning large
gelatine-like substrates, which defines MMP specificity
and activity while degradation of short synthetic sub-
strates is independent of binding to the CBD [17]. Exo-
sites, that is, outside the catalytic center, are the crucial
if not the only structures to bind collagens to MMP-2
and MMP-9 [34].
Our findings with (GPP)10 and (GPO)10 underline the
earlier observed positive correlation between increasing
rigidity of the triple helix of the collagen analogs (PPG)6,
(PPG)12 and 3× (PPG)12 and their binding to recombinant
CBD modules [7]. They are also consistent with the find-
ing that proMMP-2 preferentially binds to triple-helical
collagenous analogs rather than to gelatinous analogs [16].
Affinities of single Col-modules of the CBD to syn-
thetic collagen analogs, for example, (PPG)12,w e r e
reported to be in the range of Kd 1.4-4.5 mM [7,35].
The strong interaction for fibrillar CI and proMMP-2
and proMMP-9 with Kd values in the low nanomolar
range (Tables 2 and 3) indicate cooperativity of all three
Col-modules when bound to extended collagen fibrils.
Obviously, owing to interaction with (GPO)10,m a j o r
conformational changes occur in the entire proMMP-2
molecule as suggested previously [7].
Collagen analog (GPO)10 binding at the CBD disturbs the
interaction with fibrillar collagen, prodomain sequence
P33-42 and gelatine
Finally, we asked how (GPO)10 competes CBD-mediated
binding of proMMP-2 to fibrillar collagen and thereby
modulates binding as well as enzymatic activity and acti-
v a t i o n .W em a d eu s eo ft h eP 33-42 peptide derived from
the prodomain of MMP-2. The P33-42 is known to bind
specifically to the Col-3 module of the CBD of MMP-2
with high affinity (Kd, 1.6 mM), thereby mimicking gela-
tine substrate [7]. (GPO)10 weakened prodomain binding
via P33-42 to proMMP-2, but this effect was not accom-
panied by strong prodomain cleavage (Figure 6B), simi-
lar to earlier reports for MMP-9 [36]. Even at high
molar excesses, P33-42 a l o n eo n l ys l i g h t l yi n h i b i t e d
proMMP-2 binding to CI (Figure 6A) and did not affect
proMMP-2 activation (Figures 6B and 6C). In MMPs
devoid of prodomain-CBD interaction or without CBD,
such as the gelatinase MMP-9 and the collagenase
MMP-13, respectively, P33-42 had no effects (data not
shown). On the other hand, P33-42 blocked (GPO)10-
mediated proMMP-2 activation (Figure 6D), strongly
implying that (GPO)10 also binds to Col-3 of the CBD.
Very high molecular excesses of (GPO)10 not only dis-
placed the prodomain from the CBD but also competed
with DQ-gelatine substrate, resulting in the reduction of
MMP-2 gelatinolytic activity (Figure 6C). Thus, affinity-
driven and concentration-dependent interactions of
(GPO)10, first with Col-1 and Col-2 and finally with
Col-3, seem to be the trigger for proMMP-2 and
proMMP-9 release and activation or for inhibition of
enzymatic activity by modulating the interaction of the
collagen-binding domain of gelatinases and their ligands:
fibrillar collagen, the MMP-2 prodomain peptide P33-42,
and the gelatine substrate.
Collagen analogs have concentration-dependent
differential effects on gelatinases
We here provide a hypothesis for concentration-depen-
dent differential effects of (GPO)10 on the binding,
release and activation and activity of (pro)MMP-2. At
low concentrations, interaction of Hyp-containing triple-
helical collagen analogs with Col-modules compete with
the binding of proMMP to collagens. Medium analog
concentrations affect proMMP binding as well as its
enzymatic activity. High-affinity binding of collagen ana-
logs to Col-1 and Col-2 and low affinity to Col-3
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in release of proMMP from the collagen depot and
autoactivation accompanied by replacement of P33-42 at
Col-3. At high concentrations, Hyp-containing triple-
helical collagen analogs compete with the substrate gela-
tine at all Col-modules, resulting in the disorientation of
gelatine at the CBD and block of enzymatic activity [37].
Collagen analogs might be used in the therapy of fibrotic
diseases
How does this model relate to potential therapeutic
options in liver fibrosis? The failure or limited success
of recent clinical trials targeting the MMP catalytic cen-
ter, for example, hydroxamic acid-based inhibitors or
peptide libraries [17,38], demand the reconsideration of
strategies. It was assumed that competition with gelatine
at the CBD might be a main mechanism for inhibition
[17]. Collagen analogs were chemically linked to a
hydroxamic acid derivative and spanned from the CBD
to the active center. Unfortunately, this straightforward
strategy did not enhance the specificity of inhibitors for
MMP-2 and MMP-9 [35]. Recently, further exosite inhi-
bitors of MMPs came into consideration [39,40]. These
earlier studies did not focus on the Hyp content and tri-
ple-helical structure of small synthetic collagen analogs.
As exemplified by (GPO)10, they can release proMMP-2
and proMMP-9 from their fibrillar collagen depots,
directly and sequentially interact with distinct Col-mod-
ules of the CBD, and interfere with the prodomain pep-
tide P33-42, thereby inducing conformational changes
and activation of MMP-2. The first hints of the potential
of collagen analogs as therapeutic tools in liver fibrosis
are given by the in situ release of proMMP-2 seques-
tered by collagen in cirrhotic liver tissue by low molecu-
lar excesses of (GPO)10 (Figure 7). Thus, our findings
establish the ECM-sequestered proform as the noncellu-
lar source of high MMP-2 activity found in the fibrosis
resolution phase supposed earlier [18-20] and Hyp-con-
taining collagen analogs as tools for targeted release of
proMMP-2 and proMMP-9 from their extracellular
depot and concomitant activation of the enzymes.
Conclusions
In conclusion, Hyp content and rigidity of the triple
helix of small collagen analogs are crucial for effective
competition with the CBD-mediated proMMP-2 and
proMMP-9 binding to nonsubstrate collagens, eventually
leading to activation of the enzyme. Thus, for example,
(GPO)10 as a model molecule for a new class of exosite
MMP modulators might mobilize the sequestered pool
of gelatinolytic activity from its noncellular storage
depot, inducing the degradation of excess ECM in fibro-
tic diseases such as liver fibrosis.
Methods
Liver tissue samples
Male Wistar rats of 200-250 g body weight were
obtained from Charles River Laboratories (Wilmington,
MA, USA). Liver fibrosis was induced by administering
200 mg/kg thioacetamide for 2 wk as described before
[41]. If not noted otherwise, reagents were purchased
from Merck (Darmstadt, Germany) or from Sigma (Dei-
senhofen, Germany) and were of the highest purity
available. Tissue samples were either fixed by 4% (vol/
vol) formalin and embedded in paraffin or prepared for
cryostat sections. Animal protocols were approved by
the regional animal study committee. Specimens of cir-
rhotic human livers were obtained from explanted livers
from patients with alcoholic cirrhosis undergoing ortho-
topic liver transplantation. Informed consent was
obtained prior to surgery. Immediately after explanta-
tion, tissue samples were snap-frozen and stored over
liquid nitrogen.
In vitro activation of MMP-2 and MMP-9
The 62-kDa actMMP-2 (Invitek, Berlin, Germany) was
released from 27.8 nM 72-kDa proMMP-2 in 1 mM
APMA in MMP activity buffer consisting of 50 mM
Tris·HCl, pH 7.5, 200 mM NaCl, 5 mM CaCl2,a n d
0.02% (vol/vol) Brij-35 for 1 h. The 86-kDa actMMP-9
(Invitek) was obtained from 217 nM 92-kDa proMMP-9
in 80-μl MMP activity buffer without Brij-35 incubated
with 100 μg/ml chymotrypsin activity-blocked trypsin
for 20 min. Tryptic digestion was terminated by 100 μg/
ml aprotinin within 10 min. All steps were performed at
37°C. These completely activated MMPs as end pro-
ducts of the in vitro activation structurally and function-
ally correspond to those found in vivo [42,43]. All
MMPs were stored in aliquots at -80°C. The (pro)MMP
activation state was routinely checked by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) substrate zymography.
Radiolabeling of pro- and actMMP-2 and pro- and
actMMP-9
Human recombinant proMMPs and in vitro activated
MMPs were obtained from Invitek [44] and were labeled
with the [
125I]-Bolton-Hunter reagent according to the
manufacturer’s instructions (PerkinElmer, Rodgau,
Germany) before the buffer was exchanged for phos-
phate-buffered saline (PBS) with 0.05% (vol/vol) Tween
20 by gel filtration as described previously [45]. Specific
radioactivity for [
125I]-MMPs was 3-9 × 10
4 cpm/ng.
Precipitation with 10% (wt/vol) trichloroacetic acid and
200 μg of BSA recovered 96% to 100% of protein-bound
radioactivity. Aliquots of labeled MMPs were frozen and
stored at -80°C. The activity and integrity were checked
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radiography with overnight exposure to Biomax MS film
(Kodak, Stuttgart, Germany) (Figure 2A).
Preparation of collagens, CI derivatives and structural
analogs
Native human CI, CIII and CVI were purified from skin
tissue and placenta. The CI single chains a1(I) and a2
(I) were obtained and modified as described previously
[45]. To prepare defined fragments, 2 mg of a1(I) were
dissolved in 1 ml of 70% (vol/vol) formic acid at room
temperature, the tubes were flushed with nitrogen for
10 min, and then 2 mg of CB were added. After incuba-
tion for 4 h at 37°C, free CB was neutralized and the
samples were lyophilized. The peptides CB3, CB6, CB7
and CB8 were separated from the reaction mixture by
gel filtration followed by ion-exchange chromatography.
The resulting peptides were characterized by amino acid
analysis and SDS-PAGE [45,46]. The CB peptides had
the following melting temperatures: CB3, 23.9°C; CB6,
26.7°C; CB7, 28.1°C; and CB8, 28.0°C [31].
The following collagen analogs and control peptides
were synthesized as described previously [47]: (GPO)10,
H-Gly-Cys-Hyp-(Gly-Pro-Hyp)10-Gly-Cys-Hyp-Gly-NH2;
(GPP)10, H-Gly-Cys-Pro-(Gly-Pro-Pro)10-Gly-Cys-Pro-
Gly-NH2; and GAP, H-Gly-Ala-Cys-(Gly-Ala-Pro)5-Gly-
Phe-Hyp-Gly-Glu-Arg-(Gly-Ala-Pro)5-NH2.P e p t i d e s
(POG)10, (PPG)10 and (POG)5 were purchased from
Peptide International (Louisville, KY, USA). Spontaneous
triple-helix assembly was approved by polarimetry over
a 10-cm path length at 1°C/min in 10 mM phosphate
buffer, pH 7.4. At 5 mg/ml, midpoints of melting curves
occurred at 82.3 ± 1.4°C for (GPO)10 and at 45.8 ± 0.8°
Cf o r( G P P ) 10. Peptide GAP was determined to be non-
helical even at 5°C. Graphs were calculated from the pri-
mary data using a custom fitting program written by D.
A. Slatter (Department of Biochemistry, University of
Cambridge, Cambridge, UK [48]) to model different
possible transitions. All collagens, CI derivatives and
peptides were stored in stock solutions of 2 mg/ml in
150 mM acetic acid at -20°C.
Histological detection of connective tissue
In rat liver samples, connective tissue was visualized
using Sirius red staining in thin sections of formalin-
fixed, paraffin-embedded tissue samples [41]. Cryostat
sections of human liver samples were fixed with 1%
(vol/vol) formalin for 10 min before being stained with
Sirius red. Slides were assessed using standard light
microscopy (Olympus, Hamburg, Germany).
In situ zymography
As described earlier, in situ zymography was performed
with cryostat sections (6 μm) of rat cirrhotic liver
[41,49]. In brief, sections were dried, overlayed with 100
μg/ml DQ-gelatine (lex/em, 495/515 nm; Molecular
Probes, Eugene, OR, USA) and 0.5% (wt/vol) low-melt
agarose in MMP activity buffer. For negative controls,
10 mM ethylenediaminetetraacetic acid or 1 mM phe-
nanthroline was included to the reaction mixture, after
which no generation of bright green fluorescence was
observed, implying inhibition of gelatinase activity [50].
Samples were inserted into coverslips and incubated at
40°C for 1 h before being transferred to room tempera-
ture for an additional 2 to 16 h. Hoechst 33342 (Invitro-
gen, Carlsbad, California, USA) nuclear dye was used for
counterstaining. Images were obtained by fluorescence
microscopy using a Nikon E800 photodocumentation
microscope (Nikon Imaging, Düsseldorf, Germany).
In situ binding of (pro)MMP-2 and (pro)MMP-9
Human cirrhotic liver cryostat sections (5 μm) were air-
dried and fixed in ice-cold acetone for 10 min. Tissue
sections were rehydrated with PBS and incubated with
25 ng/50 μl of the respective proMMP and actMMP for
30 min or were left untreated. After thorough washing
with PBS, antibodies specific for human MMP-9 (clone
MAB911; R&D Systems, Minneapolis, MN, USA) and
human MMP-2 (clone 75-7F7; Oncogene, Cambridge,
MA, USA) were applied, and primary antibody binding
was detected using the alkaline phosphatase-antialkaline
phosphatase detection system (Dako, Hamburg, Ger-
many). An irrelevant primary mouse antibody served as
control. Nuclei were counterstained with Hemalaun, and
slides were examined by standard light microscopy.
Solid-phase binding studies
ProMMP-2 and proMMP-9 or actMMP-2 and actMMP-
9 were bound to nitrocellulose and polystyrene-immobi-
lized native collagens, CI chains, CB peptides or struc-
tural analogs. Serial dilutions of collagens or CI
derivatives in 150 mM acetic acid were dotted at 3 × 3
μl to a nitrocellulose membrane with high protein-bind-
ing capacity (GE Healthcare, Munich, Germany). Air-
dried membranes were blocked with PBS and 0.3% (vol/
vol) Tween 20 overnight at 4°C, washed three times,
and incubated with 1 ng/ml [
125I]-pro- and actMMP-2
and pro- and actMMP-9 in PBS and 0.3% (vol/vol)
Tween 20 for 2 h at room temperature. Membranes
were washed again and air-dried, and bound MMP was
monitored by autoradiography. In parallel, polystyrene
microtiter plates (Dynex, Chantilly, VA, USA) were
coated with collagen proteins and peptides. Here 2 μg/
well or 200 ng/well proteins and peptides or BSA as
control were immobilized in 100 μlo f5 0m Ma m m o -
nium bicarbonate buffer, pH 9.6, by overnight incuba-
tion at 4°C. Immobilization efficacies were 20% to 45%
of total proteins [45]. Wells were washed three times
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with PBS and 0.05% (vol/vol) Tween 20 for 1 h at room
temperature. All incubation steps were performed with
2n go f[
125I]-MMPs at 4°C for 2 h. Unbound reagents
were removed by thorough washing with PBS and 0.05%
(vol/vol) Tween 20, and residual radioactivity was deter-
mined using a gamma counter (Berthold, Bad Wildbach,
Germany).
Surface plasmon resonance analysis
Sensor chip preparations and SPR measurements were
performed using a BiacoreX de v i c ea n dt h eB i a - e v a l u a -
tion software (version 3.2; Biacore, Uppsala, Sweden).
The pepsin-resistant triple-helical part of human fibrillar
CI (100 μg/ml) in 10 mM acetate coupling buffer, pH
4.8, was immobilized to a dextran matrix-sensor chip at
af l o wr a t eo f5μl/min, resulting in 5,500 resonance
units from CI covalently linked via its primary amino
groups. The control flow cell was prepared using the
coupling buffer without CI. Surfaces were activated and
blocked as described previously [51]. Immediately after
thawing, pro- and actMMP-2 and pro- and actMMP-9
were diluted to 100 to 250 nM in MMP activity buffer
or in PBS and 0.05% (vol/vol) Tween 20. For SPR mea-
surements, flow rates were 10 μl/min at 25°C, and equi-
librium was typically reached after 30 to 60 s. The
effects of (GPO)10,G A P ,( P O G ) 5, (GPP)10 and P33-42 on
MMP-2 and MMP-9 binding to CI and their enzymatic
activity were determined by adding the binding competi-
tors to the (pro- and act)MMP-2 and MMP-9 solution
in 10- to 150-fold molar excesses. Effects independent
of MMP-2 and MMP-9 activity were monitored in the
presence of Ro 28-2653 (1 μM) during SPR analysis.
The gelatinase inhibitor Ro 28-2653 was a generous gift
from H.-W. Krell (Roche, Grenzach-Wyhlen, Germany).
Sensor surfaces were regenerated with 10 mM glycine,
pH 2.3, for 1 min between runs, and sensor chips were
used up to 25 times. Kinetic parameters were analyzed
using the 1:1 binding model with drifting baseline and
subtraction of the control flow cell binding from sensor-
grams obtained with immobilized CI. Binding constants
(Kd) were calculated from the association (ka) and disso-
ciation rates (kd)o b t a i n e df r o mi n d i v i d u a lb i n d i n g
curves at different concentrations. Individual drifts of
the resonance signal were fitted locally, and c
2 values of
0.2% to 1.0% of the maximum resonance value were
considered good fits.
Fluorogenic MMP activity assay
Enzymatic activities of MMPs were studied spectro-
fluorimetrically by cleavage of fluorogenic substrates in
MMP activity buffer within 2 to 5 h. For gelatinases
800 nM MCA-Pro-Leu-Gly-Leu-Dnp-Dap-Ala-Arg-
NH2 (lex/em 328/393 nm; Bachem, Bubendorf,
Switzerland) or 10 μg/ml DQ-gelatine were used,
according to the method described by Knight et al.
[52] for collagenases 800 nM MCA-Pro-Cha-Gly-Nva-
His-Ala-Dpa-NH2 (lex/em 280/360 nm; Anaspec, San
José, CA, USA). In some experiments, proMMP-2 was
fully activated in the presence of 1 mM APMA prior
to the kinetic measurements. A quantity of 50 ng pro-
or actMMP-2 alone or mixed with 10- to 150-fold
molar excesses of (GPO)10,G A P ,P 33-42 or mixtures of
(GPO)10 and P33-42, were added to CI-coated, BSA-
coated (1 μg/well both) or uncoated wells containing
150 μl of the respective substrate solution. The peptide
P33-42 was purchased from the Institute of Biochemis-
try (Humboldt-University, Berlin, Germany). The influ-
ence of CI on MMP-2 enzymatic activity against the
quenched fluorescent substrate could be excluded [14].
Background subtraction (measurement without MMPs)
was applied to all curves. All experiments were per-
formed with a fluorescence microplate reader (Molecu-
lar Devices, Sunnyvale, CA, USA) and black 96-well
microtiter plates with a clear bottom (Greiner bio-one,
Frickenhausen, Germany).
Gel zymography
Samples containing MMP-2 were diluted with zymo-
gram sample buffer (Bio-Rad, Munich, Germany) and
separated on homogeneous 10% SDS-PAGE gels con-
taining 1 mg/ml (wt/vol) gelatine (Bio-Rad), washed
with excess MMP activity buffer containing 2.5% (vol/
vol) Triton X-100 to remove SDS, and incubated with
MMP activity buffer for 24 h. Gels were stained with
C o o m a s s i eB l u eR - 2 5 0 .G e l ss howing proteolytic bands
corresponding to proMMP-2 (72 kDa) or actMMP-2 (62
kDa) were scanned (Plustek, Norderstedt, Germany) and
analyzed from inverted grayscale images.
Release of in situ bound proMMP-2
ProMMP-2 was labeled using the FluoroLink Cy2
Labeling Kit according to the manufacturer’si n s t r u c -
tions (Amersham Biosciences, Freiburg, Germany).
Unbound fluorescent dye was removed by ultrafiltra-
tion (Nanosep, Lund, Sweden), and labeling success
was monitored using a fluorescence microplate reader
(lex/em, 489/506 nm). Serial cirrhotic human liver sec-
tions were covered with 1.2 μg/ml Cy2-proMMP-2 in
50 mM Tris·HCl, pH 7.4, containing 1 mM CaCl2 or
with buffer alone, and were incubated in a dark
humidified chamber for 24 h at 4°C. To study effects
of (GPO)10, a 10-fold molar excess in relation to
proMMP-2 was added to slides prior to or after Cy2-
proMMP-2 binding. Slides were washed with PBS, air-
dried, and rinsed with deionized water. Bound Cy2-
proMMP-2 was detected by fluorescence microscopy
(Olympus, Hamburg, Germany).
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Page 13 of 15Statistical Analysis
O n e - w a ya n a l y s i so fv a r i a n c ea n dT u k e y ’st e s t sw e r e
performed using SigmaStat for Windows version 2.03
(Sigmaplot, Erkrath, Germany), and P < 0.05 was con-
sidered significantly different.
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